A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Clinical trial NCT06855225 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06855225
- Sponsor
- Mehmet Akce
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2027-05-01
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.